Quick-Med Technologies, Inc. Competitively Selected By U.S. Army For a $770,000 Phase II SBIR Grant

Gainesville, Florida – July 26, 2006 – Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) announced that it has been competitively selected for the award of a Phase II grant by the U.S. Army's SBIR (Small Business Innovative Research) program (Topic No. A 5-131; Control No. 2-2682) to conduct innovative research leading to the development of a prototype wound dressing to speed the healing of wounds from chemical blister agents. The award is estimated to be worth $770,000. This wound dressing is based on advancements in the Company’s NIMBUS™ technology.

NIMBUS™ is a technology that insures a permanent chemical bond to materials such as cotton, cotton blends, paper, or polyurethane to create high-performance wound dressings, fabrics or other medical and consumer products.

The purpose of the Department of Defense’s (DoD) SBIR grant program is to harness the innovative talents of the nation's small technology companies for U.S. military and economic strength. This program funds early-stage R&D projects at small technology companies -- projects which serve a DoD need and have the potential for commercialization in private sector and/or military markets.

Quick-Med Technologies successfully completed the Phase I SBIR program. The Phase II SBIR award is estimated to be $770,000, including $40,000 of additional funding under Phase I (Option) program, for up to two years for prototype development.

"We are very pleased with this opportunity to continue our work with the U.S. Army," commented David S. Lerner, President of Quick-Med Technologies. "The potential use of our NIMBUS™ technology in a wound dressing for the military has exciting and novel commercial applications as well."

The contract award to fund the SBIR Phase II program is contingent upon successful negotiations through the assigned Contracting Officer and availability of funds.

In a related initiative, the Cooperative Research and Development Agreement (CRADA) between the U.S. Army Medical Research Institute of Chemical Defense and Quick-Med Technologies has been extended to June 30, 2011. This CRADA was originally signed on November 15, 2000 with the U.S. Army to develop a post-injury agent to the eyes and skin treatment for mustard gas exposure.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.